Literature DB >> 6852914

Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory.

P F Wright, B R Murphy, M Kervina, E M Lawrence, M A Phelan, D T Karzon.   

Abstract

An intranasal, inactivated trivalent influenza A vaccine containing 7 micrograms of A/Bangkok/1/79 (H3N2) hemagglutinin was administered to 20 children aged 1 to 6 years to assess the local and systemic immune responses to antigen delivered to the respiratory tract. Six children without prior influenza virus infection exhibited no local immune response and manifested only a minimal systemic response to the intranasal vaccine. In contrast, five individuals who were previously infected with a live attenuated influenza A H3N2 virus vaccine, although having no residual secretory antibody at the time of challenge, promptly developed a local antibody response to intranasal, inactivated antigen. Therefore, the live influenza A virus vaccine had induced memory in the local immunoglobulin A (IgA) immune system. The third group of nine children had previously been infected with wild-type H3N2 influenza virus. A majority of these children had residual local and systemic antibody at the time of challenge but they demonstrated some boosting of local IgA antibody with administration of intranasal inactivated vaccine. The competence of the secretory IgA immune system in young children in mounting primary and secondary responses to influenza antigens has important implications for approaches to prevention of influenzal illness.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6852914      PMCID: PMC348162          DOI: 10.1128/iai.40.3.1092-1095.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  Antibody response in serum and nasopharynx after naturally acquired and vaccine-induced infection with rubella virus.

Authors:  P L Ogra; D Kerr-Grant; G Umana; J Dzierba; D Weintraub
Journal:  N Engl J Med       Date:  1971-12-09       Impact factor: 91.245

2.  Poliovirus antibody response in serum and nasal secretions following intranasal inoculation with inactivated poliovaccine.

Authors:  P L Ogra; D T Karzon
Journal:  J Immunol       Date:  1969-01       Impact factor: 5.422

3.  Protective effect of antibody to parainfluenza type 1 virus.

Authors:  C B Smith; R H Purcell; J A Bellanti; R M Chanock
Journal:  N Engl J Med       Date:  1966-11-24       Impact factor: 91.245

4.  Immunization against influenza. Prevention of illness in man by aerosolized inactivated vaccine.

Authors:  R H Waldman; J J Mann; P A Small
Journal:  JAMA       Date:  1969-01-20       Impact factor: 56.272

5.  Direct demonstration in intestinal secretions of an IgA memory response to orally administered Shigella flexneri antigens.

Authors:  D F Keren; S E Kern; D H Bauer; P J Scott; P Porter
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

6.  Cellular dissemination of priming for a mucosal immune response to cholera toxin in rats.

Authors:  N F Pierce; W C Cray
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

7.  Alternative approaches to immunization of children with inactivated influenza virus vaccines.

Authors:  W P Glezen; J A Kasel; R G Webster; L H Taber
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

8.  Cold-adapted recombinant influenza A virus vaccines in seronegative young children.

Authors:  P F Wright; N Okabe; K T McKee; H F Maassab; D T Karzon
Journal:  J Infect Dis       Date:  1982-07       Impact factor: 5.226

9.  Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines.

Authors:  B R Murphy; D L Nelson; P F Wright; E L Tierney; M A Phelan; R M Chanock
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

10.  Temperature-sensitive mutants of influenza virus. 3. Further characterization of the ts-1(E) influenza A recombinant (H3N2) virus in man.

Authors:  B R Murphy; E G Chalhub; S R Nusinoff; J Kasel; R M Chanock
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

View more
  21 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.

Authors:  D C Powers; L F Fries; B R Murphy; B Thumar; M L Clements
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

3.  Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection.

Authors:  N Debard; D Buzoni-Gatel; D Bout
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

4.  IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.

Authors:  Yoshihiko Terauchi; Kaori Sano; Akira Ainai; Shinji Saito; Yuki Taga; Kiyoko Ogawa-Goto; Shin-Ichi Tamura; Takato Odagiri; Masato Tashiro; Mikiya Fujieda; Tadaki Suzuki; Hideki Hasegawa
Journal:  Hum Vaccin Immunother       Date:  2018-04-09       Impact factor: 3.452

Review 5.  Is there a role for a mucosal influenza vaccine in the elderly?

Authors:  E M Corrigan; R L Clancy
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

6.  Immunoglobulin A-deficient mice exhibit altered T helper 1-type immune responses but retain mucosal immunity to influenza virus.

Authors:  Yongxin Zhang; Susan Pacheco; Catherine L Acuna; Kirsten C Switzer; Ying Wang; Xyanthine Gilmore; Gregory R Harriman; Innocent N Mbawuike
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

7.  A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging.

Authors:  Hideki Asanuma; Normaiza Binti Zamri; Shinichi Sekine; Yoshiko Fukuyama; Daisuke Tokuhara; Rebekah S Gilbert; Tatsuya Fukuiwa; Keiko Fujihashi; Tetsutaro Sata; Masato Tashiro; Kohtaro Fujihashi
Journal:  Vaccine       Date:  2011-11-17       Impact factor: 3.641

Review 8.  Mucosal vaccines for the prevention of influenza.

Authors:  R L Clancy
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

9.  Attenuation of wild-type human influenza A virus by acquisition of the PA polymerase and matrix protein genes of influenza A/Ann Arbor/6/60 cold-adapted donor virus.

Authors:  M H Snyder; M L Clements; D De Borde; H F Maassab; B R Murphy
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948

10.  Active synthesis of hemagglutinin-specific immunoglobulin A by lung cells of mice that were immunized intragastrically with inactivated influenza virus vaccine.

Authors:  K S Chen; D B Burlington; G V Quinnan
Journal:  J Virol       Date:  1987-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.